| An atlas of human regulatory T helper-like cells reveals features of Th2-like Tregs that support a tumorigenic environment L Halim, M Romano, R McGregor, I Correa, P Pavlidis, N Grageda, ... Cell reports 20 (3), 757-770, 2017 | 133 | 2017 |
| Systematic review: bile acids and intestinal inflammation‐luminal aggressors or regulators of mucosal defence? P Pavlidis, N Powell, RP Vincent, D Ehrlich, I Bjarnason, B Hayee Alimentary pharmacology & therapeutics 42 (7), 802-817, 2015 | 129 | 2015 |
| Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care P Pavlidis, FJQ Chedgy, JA Tibble Scandinavian journal of gastroenterology 48 (9), 1048-1054, 2013 | 121 | 2013 |
| Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management MA Samaan, P Pavlidis, S Papa, N Powell, PM Irving Nature Reviews Gastroenterology & Hepatology 15 (4), 222-234, 2018 | 97 | 2018 |
| Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells N Powell, E Pantazi, P Pavlidis, A Tsakmaki, K Li, F Yang, A Parker, C Pin, ... Gut 69 (3), 578-590, 2020 | 93 | 2020 |
| Human retinoic acid–regulated CD161+ regulatory T cells support wound repair in intestinal mucosa GAM Povoleri, E Nova-Lamperti, C Scottà, G Fanelli, YC Chen, PD Becker, ... Nature immunology 19 (12), 1403-1414, 2018 | 92 | 2018 |
| PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease M Mahler, DP Bogdanos, P Pavlidis, MJ Fritzler, E Csernok, ... Clinica chimica acta 424, 267-273, 2013 | 88 | 2013 |
| Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation? CD Moulton, P Pavlidis, C Norton, S Norton, C Pariante, B Hayee, ... Clinical & Experimental Immunology 197 (3), 308-318, 2019 | 87 | 2019 |
| Improved Outcome of Severe Acute Pancreatitis in the Intensive Care Unit MO Polychronis Pavlidis, Siobhan Crichton, Joanna Lemmich Smith, David ... Critical Care Research and Practice 2013, 2013 | 86 | 2013 |
| Complement receptor CD46 co-stimulates optimal human CD8+ T cell effector function via fatty acid metabolism G Arbore, EE West, J Rahman, G Le Friec, N Niyonzima, M Pirooznia, ... Nature communications 9 (1), 4186, 2018 | 83 | 2018 |
| Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease DP Bogdanos, D Roggenbuck, D Reinhold, T Wex, P Pavlidis, ... BMC gastroenterology 12, 1-9, 2012 | 77 | 2012 |
| Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn’s disease P Pavlidis, O Romanidou, D Roggenbuck, MG Mytilinaiou, F Al-Sulttan, ... Journal of Immunology Research 2012, 2012 | 62 | 2012 |
| Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres MA Samaan, P Pavlidis, E Johnston, B Warner, J Digby-Bell, ... Frontline Gastroenterology 8 (3), 196-202, 2017 | 53* | 2017 |
| Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy P Pavlidis, A Tsakmaki, E Pantazi, K Li, D Cozzetto, J Digby-Bell, F Yang, ... Nature communications 13 (1), 5820, 2022 | 49 | 2022 |
| Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD—disease outcome and response to therapy B Verstockt, NM Noor, UM Marigorta, P Pavlidis, P Deepak, RC Ungaro, ... Journal of Crohn's and Colitis 15 (9), 1431-1442, 2021 | 47 | 2021 |
| British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis N Powell, H Ibraheim, T Raine, RA Speight, S Papa, O Brain, M Green, ... The Lancet Gastroenterology & Hepatology 5 (7), 679-697, 2020 | 44 | 2020 |
| Diagnostic and clinical significance of Crohn’s disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies P Pavlidis, L Komorowski, B Teegen, C Liaskos, AL Koutsoumpas, ... Clinical Chemistry and Laboratory Medicine (CCLM) 54 (2), 249-256, 2016 | 42 | 2016 |
| Long-term safety and efficacy of low-dose azathioprine and allopurinol cotherapy in inflammatory bowel disease: a large observational study P Pavlidis, P Stamoulos, A Abdulrehman, P Kerr, C Bull, J Duley, A Ansari Inflammatory Bowel Diseases 22 (7), 1639-1646, 2016 | 40 | 2016 |
| Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study P Pavlidis, A Ansari, J Duley, I Oancea, T Florin Inflammatory Bowel Diseases 20 (12), 2239-2246, 2014 | 40 | 2014 |
| Tofacitinib in acute severe ulcerative colitis—a real-world tertiary center experience S Honap, P Pavlidis, S Ray, E Sharma, S Anderson, JD Sanderson, ... Inflammatory bowel diseases 26 (11), e147-e149, 2020 | 37 | 2020 |
